Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results
Waterdrop Inc. (NYSE: WDH) reported strong Q3 2024 financial results with significant profitability improvement. Net profit reached RMB92.8 million, up 152.6% year-over-year. First-year premiums (FYP) grew 20.4% to RMB2,041.8 million, while net operating revenue increased 2.6% to RMB704.1 million.
The company's insurance business maintained an operating profit margin above 20%, with 14.8% quarter-over-quarter FYP growth. The medical crowdfunding platform expanded its reach, with 466 million people donating RMB66.3 billion to 3.32 million patients. The digital clinical trial solution showed 17.4% quarter-over-quarter growth, collaborating with 184 pharmaceutical companies and CROs.
By November 2024, Waterdrop had repurchased approximately 50.9 million ADSs and completed a second special cash dividend of US$7.3 million.
Waterdrop Inc. (NYSE: WDH) ha riportato risultati finanziari solidi per il terzo trimestre del 2024 con un significativo miglioramento della redditività. L'utile netto ha raggiunto 92,8 milioni di RMB, in aumento del 152,6% rispetto all'anno precedente. I premi del primo anno (FYP) sono aumentati del 20,4% a 2.041,8 milioni di RMB, mentre il fatturato operativo netto è cresciuto del 2,6% a 704,1 milioni di RMB.
Il business assicurativo dell'azienda ha mantenuto un margine di profitto operativo superiore al 20%, con una crescita FYP del 14,8% rispetto al trimestre precedente. La piattaforma di crowdfunding medicale ha ampliato la sua portata, con 466 milioni di persone che hanno donato 66,3 miliardi di RMB a 3,32 milioni di pazienti. La soluzione per studi clinici digitali ha mostrato una crescita del 17,4% rispetto al trimestre precedente, collaborando con 184 aziende farmaceutiche e CRO.
Entro novembre 2024, Waterdrop aveva riacquistato circa 50,9 milioni di ADS e completato un secondo dividendo in contante speciale di 7,3 milioni di dollari statunitensi.
Waterdrop Inc. (NYSE: WDH) reportó resultados financieros sólidos para el tercer trimestre de 2024 con una mejora significativa en la rentabilidad. La utilidad neta alcanzó 92,8 millones de RMB, un aumento del 152,6% interanual. Las primas de primer año (FYP) crecieron un 20,4% hasta 2.041,8 millones de RMB, mientras que los ingresos operativos netos aumentaron un 2,6% hasta 704,1 millones de RMB.
El negocio de seguros de la compañía mantuvo un margen de utilidad operativa superior al 20%, con un crecimiento FYP del 14,8% respecto al trimestre anterior. La plataforma de crowdfunding médico amplió su alcance, con 466 millones de personas donando 66,3 mil millones de RMB a 3,32 millones de pacientes. La solución de ensayos clínicos digitales mostró un crecimiento del 17,4% respecto al trimestre anterior, colaborando con 184 empresas farmacéuticas y CROs.
Para noviembre de 2024, Waterdrop había recomprado aproximadamente 50,9 millones de ADS y completado un segundo dividendo en efectivo especial de 7,3 millones de dólares estadounidenses.
Waterdrop Inc. (NYSE: WDH)는 2024년 3분기 강력한 재무 실적을 보고하며 수익성이 크게 개선되었다고 발표했습니다. 순이익은 92.8백만 RMB에 도달하여 전년 대비 152.6% 증가했습니다. 첫 해 보험료(FYP)는 2041.8백만 RMB로 20.4% 증가했으며, 순 운영 수익은 704.1백만 RMB로 2.6% 증가했습니다.
회사의 보험 사업은 20% 이상의 운영 이익률을 유지하고 있으며, 전 분기 대비 FYP가 14.8% 증가했습니다. 의료 크라우드펀딩 플랫폼은 4억 6,600만 명이 663억 RMB를 332만 명의 환자에게 기부하면서 범위를 확장했습니다. 디지털 임상 시험 솔루션은 17.4%의 분기 대비 성장을 보여주며 184개의 제약사 및 CRO와 협력하고 있습니다.
2024년 11월까지 Waterdrop은 약 5090만 개의 ADS를 재구매했으며, 730만 달러의 두 번째 특별 현금 배당금을 완료했습니다.
Waterdrop Inc. (NYSE: WDH) a annoncé de solides résultats financiers pour le troisième trimestre 2024, avec une amélioration significative de la rentabilité. Le bénéfice net a atteint 92,8 millions RMB, en hausse de 152,6 % par rapport à l'année précédente. Les primes de première année (FYP) ont augmenté de 20,4 % pour atteindre 2.041,8 millions RMB, tandis que le chiffre d'affaires opérationnel net a augmenté de 2,6 % pour atteindre 704,1 millions RMB.
L'activité d'assurance de l'entreprise a maintenu une marge bénéficiaire opérationnelle supérieure à 20 %, avec une croissance des FYP de 14,8 % par rapport au trimestre précédent. La plateforme de financement participatif médical a élargi son champ d'action, avec 466 millions de personnes ayant fait don de 66,3 milliards de RMB à 3,32 millions de patients. La solution d'essai clinique numérique a montré une croissance de 17,4 % par rapport au trimestre précédent, collaborant avec 184 entreprises pharmaceutiques et CRO.
En novembre 2024, Waterdrop avait racheté environ 50,9 millions d'ADS et avait effectué un deuxième dividende en espèces spécial de 7,3 millions de dollars américains.
Waterdrop Inc. (NYSE: WDH) hat für das dritte Quartal 2024 starke Finanzzahlen veröffentlicht, mit einer deutlichen Verbesserung der Rentabilität. Der Nettogewinn erreichte 92,8 Millionen RMB, was einem Anstieg von 152,6 % im Vergleich zum Vorjahr entspricht. Die Erstanlageprämien (FYP) stiegen um 20,4 % auf 2.041,8 Millionen RMB, während der Nettobetriebsumsatz um 2,6 % auf 704,1 Millionen RMB zunahm.
Das Versicherungsgeschäft des Unternehmens hielt die operative Gewinnmarge über 20 %, mit einem FYP-Wachstum von 14,8 % im Quartalsvergleich. Die medizinische Crowdfunding-Plattform erweiterte ihre Reichweite, wobei 466 Millionen Menschen 66,3 Milliarden RMB an 3,32 Millionen Patienten spendeten. Die digitale klinische Studienlösung zeigte ein Wachstum von 17,4 % im Quartalsvergleich und kooperierte mit 184 Pharmaunternehmen und CROs.
Bis November 2024 hatte Waterdrop etwa 50,9 Millionen ADS zurückgekauft und eine zweite Sonderdividende von 7,3 Millionen US-Dollar ausgeschüttet.
- Net profit grew 152.6% YoY to RMB92.8 million
- FYP increased 20.4% YoY to RMB2,041.8 million
- Insurance business maintained >20% operating profit margin
- Operating revenue grew 2.6% YoY to RMB704.1 million
- Digital clinical trial solution revenue increased 17.4% QoQ
- Positive operating cash flow maintained in Q3 2024
- Insurance-related income decreased 3.0% YoY to RMB600.7 million
- Digital clinical trial solution income declined 12.1% YoY
- Crowdfunding service fees decreased 5.0% QoQ
Insights
Waterdrop delivered strong Q3 2024 results with significant profitability improvement. Net profit surged
Key positives include robust premium growth in both short and long-term insurance products,
The company's AI initiatives show promising commercial traction. The 'AI Consultant' powered by their proprietary large language model is already generating millions in monthly premiums. The launch of 'AI Top Sales Platform 3.0' for customizing AI sales agents and the deployment of 'AI Service Quality Agent' demonstrate meaningful progress in AI monetization and operational efficiency improvements.
The digital transformation efforts across insurance distribution and clinical trial patient recruitment showcase Waterdrop's successful pivot toward technology-driven solutions. With 909 patients enrolled and 88 new programs initiated in Q3, the platform is gaining momentum in the digital clinical trials space.
Financial and Operational Highlights for the Third Quarter of 2024
- Marked improvement in profitability and healthy liquidity: In the third quarter of 2024, net profit attributable to our ordinary shareholders reached
RMB92.8 million , representing a year-over-year growth of152.6% . As of September 30, 2024, we continued to generate positive operating cash flow during the third quarter of 2024. - Strong business performance: For the third quarter of 2024, the first-year premiums ("FYP") generated through our insurance business amounted to
RMB2,041.8 million (US ), representing an increase of$290.9 million 20.4% year over year. Net operating revenue wasRMB704.1 million (US ), representing an increase of$100.3 million 2.6% year over year. - Expanded crowdfunding coverage: As of September 30, 2024, around 466 million people cumulatively had donated an aggregate of
RMB66.3 billion to 3.32 million patients through Waterdrop Medical Crowdfunding. - Dependable performance in patient recruitment: As of September 30, 2024, the Company had cumulatively enrolled over 9,500 patients into 1,137 clinical trial programs through the E-Find Platform.
Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "We are delighted to announce another quarter of robust profitability, with net profit attributable to ordinary shareholders reaching 2.5 times that of the third quarter last year.
Our insurance business has achieved a
This quarter marks a significant milestone for our medical crowdfunding business and the industry as a whole, following the issuance of the 'Measures for Administration of Online Service Platforms for Individuals Seeking Financial Help' released by Ministry of Civil Affairs of PRC and other government departments on September 5, 2024. The Measures for Administration officially announce the legal framework of fundraising sector, and offer guidance on management and information transparency.
During this quarter, our digital clinical trial solution income continued its growth, realizing a quarter-over-quarter increase of
We are also delighted to report notable progress in AI. Internally, 'AI Consultant', a conversational AI agent powered by our 'Waterdrop Guardian' large language model, has reached the capacity to generate million yuan in monthly premiums by serving user inquires. Meanwhile, a new application, 'AI Service Quality Agent', was deployed to streamline the service quality inspection process by replacing manual work. Externally, we launched 'AI Top Sales Platform 3.0', a conversational AI platform that customizes AI sales agents for businesses, and have initiated pilots with insurance carriers and companies in non-insurance sectors.
We value the trust from our investors and prioritize shareholder returns. By the end of November 2024, the Company had cumulatively repurchased approximately 50.9 million ADSs from the open market. Moreover, we recently completed our second special cash dividend of approximately
With our strong execution capability, ample cash reserves and continuous profitability, we will continue to focus on fostering sustainable growth, and strive to deliver substantial returns to our shareholders and investors."
Financial Results for the Third Quarter of 2024
Operating revenue, net
Net operating revenue for the third quarter of 2024 increased by
- Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to
RMB600.7 million (US ) in the third quarter of 2024, representing a decrease of$85.6 million 3.0% year over year fromRMB619.3 million for the third quarter of 2023, which was mainly due to the decrease in technical service income. On a quarter-over-quarter basis, insurance-related income increased by4.7% . - Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the third quarter of 2024, we generated
RMB65.8 million (US ) in service fees, representing an increase of$9.4 million 83.0% year over year fromRMB36.0 million for the third quarter of 2023. On a quarter-over-quarter basis, crowdfunding service fees decreased by5.0% . - Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the third quarter of 2024, our digital clinical trial solution income amounted to
RMB24.3 million (US ), representing a decrease of$3.5 million 12.1% fromRMB27.6 million in the same period of 2023. On a quarter-over-quarter basis, digital clinical trial solution income increased by17.4% .
Operating costs and expenses
Operating costs and expenses decreased by
- Operating costs increased by
9.1% year over year toRMB340.6 million (US ) for the third quarter of 2024, as compared with$48.5 million RMB312.3 million for the third quarter of 2023, which was primarily driven by (i) an increase ofRMB46.5 million in costs of referral and service fees, partially offset by (ii) a decrease ofRMB10.0 million in personnel costs, and (iii) a decrease ofRMB7.0 million in the costs for crowdfunding consultants team. On a quarter-over-quarter basis, operating costs increased by6.7% fromRMB319.1 million , primarily due to (i) an increase ofRMB32.6 million in costs of referral and service fees, partially offset by (ii) a decrease ofRMB8.9 million in personnel costs, and (iii) a decrease ofRMB5.1 million in the costs for crowdfunding consultants team. - Sales and marketing expenses decreased by
7.7% year over year toRMB173.2 million (US ) for the third quarter of 2024, as compared with$24.7 million RMB187.7 million for the same quarter of 2023. The decrease was primarily due to (i) a decrease ofRMB36.5 million in personnel costs and share-based compensation expenses, partially offset by (ii) an increase ofRMB21.1 million in marketing expenses to third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses increased by10.0% fromRMB157.4 million , primarily due to (i) an increase ofRMB14.4 million in marketing expenses to third-party traffic channels, (ii) an increase ofRMB4.5 million in outsourced sales and marketing service fees to third parties, and partially offset by (iii) a decrease ofRMB3.1 million in sales and marketing personnel costs and share-based compensation expenses - General and administrative expenses decreased by
3.2% year over year toRMB111.0 million (US ) for the third quarter of 2024, compared with$15.8 million RMB114.6 million for the same quarter of 2023. The year-over-year variance was due to (i) a decrease ofRMB24.8 million in professional service fees, (ii) a decrease ofRMB5.8 million in personnel costs and share-based compensation expenses, partially offset by (iii) an increase ofRMB10.6 million in allowance for doubtful accounts, and (iv) an increase ofRMB20.6 million impairment loss for intangible assets related to the acquisition of Shenzhen Cunzhen Qiushi Technology Co., Ltd. and its subsidiaries ("Shenlanbao"). On a quarter-over-quarter basis, general and administrative expenses increased by18.1% fromRMB94.0 million , due to (i) an increase ofRMB20.6 million impairment loss for intangible assets related to the acquisition of Shenlanbao, (ii) an increase ofRMB6.9 million in personnel costs and share-based compensation expenses, partially offset by (iii) a decrease ofRMB6.8 million in professional service fees, and (iv) a decrease ofRMB3.1 million allowance for doubtful accounts. - Research and development expenses decreased by
28.4% year over year toRMB53.0 million (US ) for the third quarter of 2024, compared with$7.5 million RMB73.9 million for the same period of 2023. The decrease was primarily due to a decrease ofRMB18.9 million in personnel costs and share-based compensation expenses. On a quarter-over-quarter basis, research and development expenses remained stable.
Operating profit for the third quarter of 2024 was
Interest income for the third quarter of 2024 was
Income tax benefit for the third quarter of 2024 was
Net profit attributable to the Company's ordinary shareholders for the third quarter of 2024 was
Adjusted net profit attributable to the Company's ordinary shareholders (non-GAAP(1)) for the third quarter of 2024 was
Cash position(2)
As of September 30, 2024, cash position of the Company was
(1) See the sections entitled "Non-GAAP Financial Measure" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP |
Share Repurchase Programs
Pursuant to the share repurchase programs launched in September 2021, September 2022, September 2023 and September 2024, respectively, we had cumulatively repurchased approximately 50.9 million ADSs from the open market with cash for a total consideration of approximately
Supplemental Information
We organize and report our business in three operating segments:
- Insurance, which mainly includes Waterdrop Insurance Marketplace, Shenlanbao Insurance Marketplace and technical support service;
- Crowdfunding, which mainly includes Waterdrop Medical Crowdfunding; and
- Others, which mainly include Digital Clinical Trial Solution and other new initiatives.
The table below sets forth the segment operating results, with the nine-month comparative figures retrospectively adjusted to conform to this presentation.
For the Three Months Ended | For the Nine Months Ended | |||||||||||||
September 30, | June 30, | September 30, | September | September 30, | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
(All amounts in thousands) | ||||||||||||||
Operating revenue, net | ||||||||||||||
Insurance | 619,269 | 573,832 | 600,726 | 85,603 | 1,753,049 | 1,781,335 | 253,838 | |||||||
Crowdfunding | 35,971 | 69,323 | 65,839 | 9,382 | 122,670 | 202,512 | 28,858 | |||||||
Others | 31,238 | 33,001 | 37,576 | 5,354 | 95,624 | 101,150 | 14,414 | |||||||
Total consolidated operating | 686,478 | 676,156 | 704,141 | 100,339 | 1,971,343 | 2,084,997 | 297,110 | |||||||
Operating profit/(loss) | ||||||||||||||
Insurance | 145,200 | 122,955 | 122,501 | 17,457 | 399,914 | 374,619 | 53,383 | |||||||
Crowdfunding | (68,793) | (22,936) | (17,902) | (2,551) | (194,058) | (73,075) | (10,413) | |||||||
Others | (43,713) | (27,450) | (31,716) | (4,520) | (128,157) | (90,598) | (12,911) | |||||||
Total segment operating | 32,694 | 72,569 | 72,883 | 10,386 | 77,699 | 210,946 | 30,059 | |||||||
Unallocated item** | (34,762) | (20,205) | (46,413) | (6,614) | (111,081) | (85,748) | (12,219) | |||||||
Total consolidated operating | (2,068) | 52,364 | 26,470 | 3,772 | (33,382) | 125,198 | 17,840 | |||||||
Total other income | 36,914 | 38,366 | 60,842 | 8,670 | 126,520 | 141,989 | 20,233 | |||||||
Profit before income tax | 34,846 | 90,730 | 87,312 | 12,442 | 93,138 | 267,187 | 38,073 | |||||||
Income tax benefit/(expense) | 1,479 | (7,026) | 7,843 | 1,118 | 14,609 | (7,771) | (1,107) | |||||||
Net profit | 36,325 | 83,704 | 95,155 | 13,560 | 107,747 | 259,416 | 36,966 | |||||||
* Starting from the second quarter of 2023, our chief operating decision maker began managing the business through three | ||||||||||||||
** The share-based compensation and impairment of intangible assets acquired from business combination represent |
Exchange Rate
This announcement contains translations of certain RMB amounts into
Non-GAAP Financial Measure
The Company uses non-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation expense attributable to our ordinary shareholders, foreign currency exchange gain or losses, impairment of intangible assets acquired from business combination and related tax effects on non-GAAP adjustments
The non-GAAP financial measure is not presented in accordance with
The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable
For more information on the non-GAAP financial measure, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.
Safe Harbor Statement
This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the
Conference Call Information
Waterdrop's management team will hold a conference call on December 11, 2024 at 7:00 AM
International: | 1-412-317-6061 |
United States Toll Free: | 1-888-317-6003 |
Hong Kong Toll Free: | 800-963976 |
852-58081995 | |
Mainland | 4001-206115 |
Chinese Line (Mandarin) Entry Number: | 4533234 |
English Interpretation Line (Listen-only Mode) Entry Number: | 2061532 |
Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.
Telephone replays will be accessible two hours after the conclusion of the conference call until December 18, 2024 by dialing the following numbers:
United States Toll Free: | 1-877-344-7529 |
International: | 1-412-317-0088 |
Chinese Line Access Code: | 6305770 |
English Interpretation Line Access Code: | 9765426 |
A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/.
About Waterdrop Inc.
Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.
For investor inquiries, please contact
Waterdrop Inc.
IR@shuidi-inc.com
WATERDROP INC. | |||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
(All amounts in thousands, unless otherwise noted) | |||||
As of | |||||
December 31, 2023 | September 30, 2024 | ||||
RMB | RMB | USD | |||
Assets | |||||
Current assets | |||||
Cash and cash equivalents | 396,905 | 442,145 | 63,005 | ||
Restricted cash | 577,121 | 474,683 | 67,642 | ||
Short-term investments | 2,996,527 | 1,912,873 | 272,582 | ||
Accounts receivable, net | 693,110 | 755,427 | 107,647 | ||
Current contract assets | 572,871 | 631,507 | 89,989 | ||
Amount due from related parties | 65 | 250 | 36 | ||
Prepaid expense and other assets | 189,846 | 192,153 | 27,381 | ||
Total current assets | 5,426,445 | 4,409,038 | 628,282 | ||
Non-current assets | |||||
Non-current contract assets | 134,383 | 141,262 | 20,130 | ||
Property, equipment and software, net | 33,878 | 237,616 | 33,860 | ||
Intangible assets, net | 177,407 | 153,043 | 21,808 | ||
Long-term investments | 211,758 | 1,122,407 | 159,942 | ||
Right of use assets, net | 59,851 | 55,149 | 7,859 | ||
Deferred tax assets | 24,190 | 29,297 | 4,175 | ||
Goodwill | 80,751 | 80,751 | 11,507 | ||
Total non-current assets | 722,218 | 1,819,525 | 259,281 | ||
Total assets | 6,148,663 | 6,228,563 | 887,563 | ||
Liabilities, Mezzanine Equity and Shareholders' Equity | |||||
Current liabilities | |||||
Amount due to related parties | 9,509 | 10,043 | 1,431 | ||
Insurance premium payables | 591,953 | 493,596 | 70,337 | ||
Accrued expenses and other current liabilities | 597,684 | 724,610 | 103,256 | ||
Short-term loans | 137,557 | 148,544 | 21,167 | ||
Current lease liabilities | 32,908 | 35,946 | 5,122 | ||
Total current liabilities | 1,369,611 | 1,412,739 | 201,313 | ||
Non-current liabilities | |||||
Non-current lease liabilities | 27,293 | 18,464 | 2,631 | ||
Deferred tax liabilities | 73,305 | 85,713 | 12,214 | ||
Total non-current liabilities | 100,598 | 104,177 | 14,845 | ||
Total liabilities | 1,470,209 | 1,516,916 | 216,158 | ||
Mezzanine Equity | |||||
Redeemable non-controlling interests | 92,760 | 90,449 | 12,889 | ||
Shareholders' equity | |||||
Class A ordinary shares | 112 | 113 | 16 | ||
Class B ordinary shares | 27 | 27 | 4 | ||
Treasury stock | (12) | (15) | (2) | ||
Additional paid-in capital | 7,003,423 | 6,821,616 | 972,073 | ||
Accumulated other comprehensive income | 144,107 | 99,693 | 14,206 | ||
Accumulated deficit | (2,561,963) | (2,300,236) | (327,781) | ||
Total shareholders' equity | 4,585,694 | 4,621,198 | 658,516 | ||
Total liabilities, mezzanine equity and shareholders' equity | 6,148,663 | 6,228,563 | 887,563 |
WATERDROP INC. | ||||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | ||||||||||||||
(All amounts in thousands, except for share and per share data, or otherwise noted) | ||||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||
September 30, 2023 | June 30, 2024 | September 30, 2024 | September 30, 2023 | September 30, 2024 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Operating revenue, net | 686,478 | 676,156 | 704,141 | 100,339 | 1,971,343 | 2,084,997 | 297,110 | |||||||
Operating costs and expenses(i) | ||||||||||||||
Operating costs | (312,278) | (319,101) | (340,560) | (48,529) | (893,401) | (990,904) | (141,203) | |||||||
Sales and marketing expenses | (187,685) | (157,413) | (173,172) | (24,677) | (565,634) | (512,731) | (73,064) | |||||||
General and administrative expenses | (114,641) | (93,978) | (110,988) | (15,816) | (306,436) | (293,927) | (41,884) | |||||||
Research and development expenses | (73,942) | (53,300) | (52,951) | (7,545) | (239,254) | (162,237) | (23,119) | |||||||
Total operating costs and expenses | (688,546) | (623,792) | (677,671) | (96,567) | (2,004,725) | (1,959,799) | (279,270) | |||||||
Operating (loss)/profit | (2,068) | 52,364 | 26,470 | 3,772 | (33,382) | 125,198 | 17,840 | |||||||
Other income | ||||||||||||||
Interest income | 32,890 | 37,510 | 36,005 | 5,131 | 101,384 | 113,319 | 16,148 | |||||||
Foreign currency exchange (loss)/gain | (3,734) | (444) | 7,909 | 1,127 | (2,614) | 8,979 | 1,279 | |||||||
Others, net | 7,758 | 1,300 | 16,928 | 2,412 | 27,750 | 19,691 | 2,806 | |||||||
Profit before income tax | 34,846 | 90,730 | 87,312 | 12,442 | 93,138 | 267,187 | 38,073 | |||||||
Income tax benefit/(expense) | 1,479 | (7,026) | 7,843 | 1,118 | 14,609 | (7,771) | (1,107) | |||||||
Net profit | 36,325 | 83,704 | 95,155 | 13,560 | 107,747 | 259,416 | 36,966 | |||||||
Net (loss)/profit attributable to mezzanine | (417) | (4,586) | 2,350 | 335 | (417) | (2,311) | (329) | |||||||
Net profit attributable to ordinary shareholders | 36,742 | 88,290 | 92,805 | 13,225 | 108,164 | 261,727 | 37,295 | |||||||
Other comprehensive income: | ||||||||||||||
Foreign currency translation adjustment, net of | 8,983 | 13,497 | (83,054) | (11,835) | 76,803 | (44,414) | (6,329) | |||||||
Unrealized loss on available for sale | - | - | - | - | (1,551) | - | - | |||||||
Total comprehensive income | 45,308 | 97,201 | 12,101 | 1,725 | 182,999 | 215,002 | 30,637 | |||||||
Total comprehensive (loss)/profit attributable | (417) | (4,586) | 2,350 | 335 | 7,074 | (2,311) | (329) | |||||||
Total comprehensive income attributable to | 45,725 | 101,787 | 9,751 | 1,390 | 175,925 | 217,313 | 30,966 | |||||||
Weighted average number of ordinary shares | ||||||||||||||
Basic | 3,719,628,339 | 3,660,589,600 | 3,624,431,887 | 3,624,431,887 | 3,793,678,209 | 3,660,415,080 | 3,660,415,080 | |||||||
Diluted | 3,808,529,672 | 3,734,346,444 | 3,689,357,838 | 3,689,357,838 | 3,921,118,226 | 3,726,590,324 | 3,726,590,324 | |||||||
Net profit per share attributable to ordinary shareholders | ||||||||||||||
Basic | 0.01 | 0.02 | 0.03 | 0.00 | 0.03 | 0.07 | 0.01 | |||||||
Diluted | 0.01 | 0.02 | 0.03 | 0.00 | 0.03 | 0.07 | 0.01 | |||||||
(i) Share-based compensation expenses are included in the operating costs and expenses as follows. | ||||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||
September 30, 2023 | June 30, 2024 | September 30, 2024 | September 30, 2023 | September 30, 2024 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Sales and marketing expenses | (8,944) | (1,320) | (1,993) | (284) | (33,361) | (5,133) | (731) | |||||||
General and administrative expenses | (22,060) | (16,285) | (21,297) | (3,035) | (66,642) | (51,909) | (7,397) | |||||||
Research and development expenses | (3,758) | (2,600) | (2,563) | (365) | (11,078) | (8,146) | (1,161) | |||||||
Total | (34,762) | (20,205) | (25,853) | (3,684) | (111,081) | (65,188) | (9,289) |
WATERDROP INC. | ||||||||||||||
RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS | ||||||||||||||
(All amounts in thousands, unless otherwise noted) | ||||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||
September 30, 2023 | June 30, 2024 | September 30, 2024 | September 30, 2023 | September 30, 2024 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Net profit attributable to the Company's ordinary | 36,742 | 88,290 | 92,805 | 13,225 | 108,164 | 261,727 | 37,295 | |||||||
Add: | ||||||||||||||
Share-based compensation expense attributable to | 33,810 | 20,015 | 25,673 | 3,658 | 110,130 | 64,948 | 9,255 | |||||||
Foreign currency exchange loss/(gain) | 3,734 | 444 | (7,909) | (1,127) | 2,614 | (8,979) | (1,279) | |||||||
Impairment of intangible assets acquired from | - | - | 20,560 | 2,930 | - | 20,560 | 2,930 | |||||||
Tax effects on non-GAAP adjustments | - | - | (5,140) | (732) | - | (5,140) | (732) | |||||||
Adjusted net profit attributable to the Company's | 74,286 | 108,749 | 125,989 | 17,954 | 220,908 | 333,116 | 47,469 |
View original content:https://www.prnewswire.com/news-releases/waterdrop-inc-announces-third-quarter-2024-unaudited-financial-results-302328817.html
SOURCE Waterdrop Inc.
FAQ
What was Waterdrop's (WDH) net profit in Q3 2024?
How much did WDH's First-Year Premiums (FYP) grow in Q3 2024?
What was WDH's operating revenue in Q3 2024?
How many ADSs has WDH repurchased as of November 2024?